Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of
DHP107 (Oral Paclitaxel, Korea brand name: Liporaxel®) compared to IV Paclitaxel in patients
with Recurrent or Metastatic Breast Cancer.